BR112022024728A2 - Compostos e métodos para tratamento de distúrbios oftalmológicos - Google Patents

Compostos e métodos para tratamento de distúrbios oftalmológicos

Info

Publication number
BR112022024728A2
BR112022024728A2 BR112022024728A BR112022024728A BR112022024728A2 BR 112022024728 A2 BR112022024728 A2 BR 112022024728A2 BR 112022024728 A BR112022024728 A BR 112022024728A BR 112022024728 A BR112022024728 A BR 112022024728A BR 112022024728 A2 BR112022024728 A2 BR 112022024728A2
Authority
BR
Brazil
Prior art keywords
methods
compounds
treatment
ophthalmological
reducing
Prior art date
Application number
BR112022024728A
Other languages
English (en)
Portuguese (pt)
Inventor
Kelly Darren
Papadimitriou Michelle
Burns Chris
Daniels Eric
Original Assignee
Occurx Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901856A external-priority patent/AU2020901856A0/en
Application filed by Occurx Pty Ltd filed Critical Occurx Pty Ltd
Publication of BR112022024728A2 publication Critical patent/BR112022024728A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112022024728A 2020-06-05 2021-06-03 Compostos e métodos para tratamento de distúrbios oftalmológicos BR112022024728A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901856A AU2020901856A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901858A AU2020901858A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
PCT/US2021/035749 WO2021247900A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Publications (1)

Publication Number Publication Date
BR112022024728A2 true BR112022024728A2 (pt) 2023-03-07

Family

ID=78829970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024728A BR112022024728A2 (pt) 2020-06-05 2021-06-03 Compostos e métodos para tratamento de distúrbios oftalmológicos

Country Status (11)

Country Link
US (1) US20230270703A1 (enExample)
EP (1) EP4161527A4 (enExample)
JP (1) JP2023529845A (enExample)
KR (1) KR20230024331A (enExample)
CN (1) CN116033901A (enExample)
AU (1) AU2021284380A1 (enExample)
BR (1) BR112022024728A2 (enExample)
CA (1) CA3185849A1 (enExample)
IL (1) IL298733A (enExample)
MX (1) MX2022015327A (enExample)
WO (2) WO2021247901A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197681A1 (en) * 2021-03-17 2022-09-22 Occurx Pty Ltd Compounds for the treatment of disorders and salts and polymorphs thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
WO1997029744A1 (en) * 1996-02-15 1997-08-21 Kissei Pharmaceutical Co., Ltd. Neovascularization inhibitor
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
EP1008347A4 (en) * 1997-04-18 2002-02-06 Kissei Pharmaceutical REMEDIES FOR PROPHYLAXIS OR TREATMENT OF DISEASES RESULTING IN EXCESSIVE PROLIFERATION OF PIGMENTAL RETINE EPITHELIAL CELLS
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
JP2011006406A (ja) * 2009-05-29 2011-01-13 Santen Pharmaceut Co Ltd トラニラストを含有する網膜疾患の予防または治療剤
WO2012068612A1 (en) * 2010-11-24 2012-05-31 Fibrotech Therapeutics Pty Ltd Methods of treating eye diseases associated with inflammation and vascular proliferation
US10780070B2 (en) * 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight

Also Published As

Publication number Publication date
IL298733A (en) 2023-02-01
CN116033901A (zh) 2023-04-28
MX2022015327A (es) 2023-02-22
US20230270703A1 (en) 2023-08-31
KR20230024331A (ko) 2023-02-20
WO2021247900A1 (en) 2021-12-09
WO2021247901A1 (en) 2021-12-09
EP4161527A4 (en) 2024-06-26
CA3185849A1 (en) 2021-12-09
EP4161527A1 (en) 2023-04-12
AU2021284380A1 (en) 2023-01-19
JP2023529845A (ja) 2023-07-12

Similar Documents

Publication Publication Date Title
Campochiaro et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial
Bertens et al. Topical drug delivery devices: A review
Sampat et al. Complications of intravitreal injections
CA2970315C (en) Use of anti-vegf agents to treat lesions in macular degeneration patients
Sisto et al. The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate‐term follow‐up
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
Shen et al. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood–retinal barrier breakdown
Gao et al. Alleviate oxidative stress in diabetic retinopathy: antioxidant therapeutic strategies
BR112017010238A2 (pt) composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular
Chapman et al. Pegaptanib: a novel approach to ocular neovascularization
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
BR112022008282A2 (pt) Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo
Xu et al. Pregabalin mediates retinal ganglion cell survival from retinal ischemia/reperfusion injury via the Akt/GSK3β/β-catenin signaling pathway
Khodabande et al. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity
MX2022015327A (es) Compuestos y metodos para el tratamiento de trastornos oculares.
BR112022018477A2 (pt) Composto derivado de pirimidina, composição compreendendo o mesmo, e seus usos na prevenção ou tratamento de doenças neurodegenerativas e câncer
Hurley et al. Examining the efficacy of verteporfin photo-dynamic therapy (PDT) at different dose & fluence levels
O’Brart Corneal collagen cross-linking for corneal ectasias
de Lima Neto et al. Micropulse versus Slow Coagulation Transscleral Cyclophotocoagulation in Refractory Glaucoma: A Randomized Clinical Trial
Paul et al. Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis
Sugano et al. Botulinum toxin for strabismus correction
BR112022014862A2 (pt) Usos terapêuticos de dulaglutida
Pangal et al. Evaluation of Photodynamic Therapy-Combined Intravitreal Bevacizumab in Age Related Macular Degeneration
Horovitz et al. Crosslinking: an updated and effective insight
Varman et al. Safety and efficacy of low-energy small incision lenticule extraction for the correction of myopia and myopic astigmatism: A retrospective analysis